Rafael Holdings Q4 2026 earnings

RFL · 2026-10-29 08:16 BMO ET · 8-K on SEC

Net loss narrowed to $9.2 million ($0.18/share) as G&A expenses fell and a $4.4 million gain on settlements offset higher R&D costs.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$244K-30.3%+36.3%Ex. 99.1, income statement
EPS (GAAP)-$0.18+35.7%+125%Ex. 99.1, income statement
Net income-$9.2M+24.0%+117%Ex. 99.1, income statement
Adj. EBITDA-$7.3M+42.7%+122%Ex. 99.1, income statement
Adj. EBITDA margin-2.99%+0.44 pp+1.20 ppEx. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses G&A $2.4M (-56.2% YoY); R&D $7.5M (flat YoY)
  • One-offs in the quarter Gain on settlement of accounts payable and convertible notes payable $4.4M; Benefit from taxes $65K
  • Effective tax rate 0.7% (prior-year 8.4%)
  • Non-GAAP bridge Adds back G&A and R&D stock-based compensation; excludes non-cash items like impairment and unrealized investment losses.

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$22.1M$30.5M$52.8M-27.5% QoQ
Weighted average shares51.6M51.2M43.0M+0.8% QoQ

Guidance

not stated in the 8-K

What drove it

  • Revenue story Revenue of $244K decreased 30.3% YoY but increased 36.3% QoQ.
  • EPS story EPS narrowed due to lower G&A expenses and a $4.4M gain on settlements.
  • One-off check Gain on settlement of accounts payable and convertible notes payable $4.4M (FY2026)

The good

  • Net loss narrowed to $0.18/share from $0.28/share YoY
  • G&A expenses decreased $3.1M YoY

The bad

  • R&D expenses increased $13.4M YoY due to Cyclo consolidation
  • Cash and cash equivalents decreased $8.4M QoQ

The ugly

  • Phase 3 TransportNPC trial did not meet its primary endpoint in the overall population

Open questions

  • The filing does not state the specific amount of the gain on Cornerstone's settlements
  • The filing does not disclose the specific amount of the $13.4M increase in Cyclo's R&D expenses
Full release

Earnings: RFL — filed 2026-10-29

Rafael Holdings, Inc. (RFL) · Form 8-K, Item 2.02 · Filed · SEC filing

Rafael Holdings Reports Fourth Quarter and Full

Year Fiscal 2026

Financial Results and Provides Corporate Update

NEWARK,

NJ – October 29, 2026 (GLOBE NEWSWIRE)

-

Rafael Holdings,

Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026.

Fiscal 2026 and Recent Corporate Highlights

Rafael Holdings, Inc. Fourth Quarter Fiscal Year 2026 Financial

Results

As of July 31, 2026, we had cash and cash equivalents of $22.1 million.

For the three months ended July 31, 2026, we recorded a net loss attributable to Rafael Holdings of $9.2 million, or $0.18 per share, versus a net loss of $12.1 million, or $0.28 per share in the year ago period.

The year over year decrease in net loss is largely attributable to a decrease in general and administrative expenses.

Research and development expenses were $7.5 million for each of the three months ended July 31, 2026 and 2025.

General and administrative expenses were $2.4 million for the three months ended July 31, 2026, compared to $5.5 million in the year ago period. The year over year decrease relates to a decrease in payroll, stock-based compensation expense and professional fees.

Rafael Holdings, Inc. Full Fiscal Year 2026 Financial Results

For the twelve months ended July 31, 2026, we recorded a net loss attributable to Rafael Holdings of $29.6 million, or $0.58 per share, versus a net loss of $30.5 million, or $1.04 per share in the year ago period.

The year over year decrease in net loss reflects a $4.4 million gain on Cornerstone’s settlements of accounts payable and convertible notes payable and the absence of prior-year unrealized losses on our investment in Cyclo, partially offset by higher research and development expenses following the consolidation of Cyclo Therapeutics in March 2025.

Research and development expenses were $24.3 million for the twelve months ended July 31, 2026, compared to $12.8 million in the year ago period. The year over year increase was primarily attributable to a $13.4 million increase in Cyclo’s research and development expenses in fiscal 2026, as well as an increase in R&D stock-based compensation expense of $0.4 million, offset by decreases in R&D payroll of $1.5 million, and in clinical trial and other expenses of $0.8 million.

General and administrative expenses were $9.7 million for the twelve months ended July 31, 2026, compared to $13.8 million in the year ago period. The decrease of $4.1 million versus the prior year is primarily attributable to decreases in professional fees of $1.3 million, primarily due to merger-related costs in the prior year, stock-based compensation expense of $1.2 million, payroll expense of $0.6 million due to terminations, and other expenses.

About Rafael Holdings, Inc.

Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is remibetadex

(Trappsol® Cyclo™), for which we have completed a pivotal Phase 3 study in Niemann-Pick Disease Type C (“NPC”) and submitted an NDA to the FDA in October 2026. NPC is a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended July 31, — (in thousands, except share and per share data)

Three Months Ended July 31, – 2026 – (unaudited)Three Months Ended July 31, – 2025 – (unaudited)Year Ended July 31, – 2026Year Ended July 31, – 2025
Revenues244350874917
Cost of infusion technology revenue106
Cost of product revenue13194228
G&A expenses2,4445,4979,70413,781
R&D expenses7,4677,54724,33312,823
Depreciation and amortization5150204288
Loss on impairment of goodwill3,050
Operating Loss-9,731-12,763-33,409-29,159
Interest income2134671,2361,996
Realized gain on available-for-sale securities178
Unrealized (loss) gain on investment - Cyclo-5,144
Unrealized (loss) gain on convertible notes receivable, due from Cyclo-719
Interest expense-6-168-333-658
Gain on settlement of accounts payable and convertible notes payable4644,422
Other income63236117310
Loss before income taxes-8,997-12,228-27,967-33,196
Benefit from taxes65174132,553
Consolidated net loss-8,932-12,054-27,954-30,643
Consolidated net loss-8,932-12,054-27,954-30,643
Net income (loss) attributable to noncontrolling interests244401,681-123
Net loss attributable to Rafael Holdings, Inc.-9,176-12,094-29,635-30,520
Loss per share attributable to common stockholders
Basic and Diluted-0.18-0.28-0.58-1.04
Weighted average number of shares used in calculation of loss per share - basic and diluted51,586,27643,011,36051,393,11829,422,221

Balance Sheet

(in thousands, except share and per share data)

July 31, – 2026July 31, – 2025
CURRENT ASSETS
Cash and cash equivalents22,07452,769
Prepaid clinical costs1,8391,045
Other receivables1,206
Accounts receivable, net of allowance for credit losses of $245 at July 31, 2026 and July 31, 2025444627
Inventory377281
Prepaid expenses and other current assets1,083786
Total current assets25,81756,714
Property and equipment, net1,5031,596
Non-current prepaid clinical costs4571,399
Convertible notes receivable classified as available-for-sale2,0441,858
Goodwill19,93919,939
Intangible assets, net863994
In-process research and development31,57531,575
Investments750
Other assets10734
TOTAL ASSETS83,055114,109
CURRENT LIABILITIES
Accounts payable7,0146,893
Accrued expenses2,9433,304
Convertible notes payable608614
Due to related parties, net355723
Other current liabilities6766
Total current liabilities10,98711,600
Accrued expenses, noncurrent3,895
Convertible notes payable, noncurrent278
Deferred income tax liability43138
Other liabilities5327
TOTAL LIABILITIES11,08515,738
EQUITY
Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of July 31, 2026 and July 31, 202588
Class B common stock, $0.01 par value; 200,000,000 shares authorized, 51,393,279 issued and outstanding (excluding treasury shares of 101,487) as of July 31, 2026, and 50,789,697 issued and outstanding (excluding treasury shares of 101,487) as of July 31, 2025514508
Additional paid-in capital323,438322,161
Accumulated deficit-261,898-232,263
Treasury stock, at cost; 101,487 Class B shares as of July 31, 2026 and July 31, 2025-168-168
Accumulated other comprehensive income related to unrealized income on available-for-sale securities544358
Accumulated other comprehensive income related to foreign currency translation adjustment3,8713,787
Total equity attributable to Rafael Holdings, Inc.66,30994,391
Noncontrolling interests5,6613,980
TOTAL EQUITY71,97098,371
TOTAL LIABILITIES AND EQUITY83,055114,109

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; the FDA’s review of our NDA for remibetadex, including whether it will be accepted for filing, granted priority review or approved; our eligibility for and ability to monetize a priority review voucher; plans regarding the further evaluation of clinical data; and the potential of our pipeline.

These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risk that the FDA may not accept for filing or approve our NDA, including because the Phase 3 TransportNPC™ study did not meet its primary endpoint in the overall population, our need for additional financing and the substantial doubt about our ability to continue as a going concern, and those disclosed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended July 31, 2026, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contact:

Barbara Ryan barbara.ryan@rafaelholdings.com

(203) 274-2825

# # #²

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Rafael Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.